kabutan

KYORIN Pharma, Last Fiscal Year Ordinary Profit Revised Upward by 91%

Wed Apr 23, 2025 12:30 pm JST Revision

4569 KYORIN Pharmaceutical Co.,Ltd. 【J-GAAP】

Guidance Update Report

KYORIN Pharmaceutical Co.,Ltd. <4569> [TSE Prime] announced a performance revision at noon (12:30) on April 23rd. The consolidated ordinary profit for the fiscal year ending March 2025 has been revised upward 91.3%, from the previous forecast of 6.9 billion yen to 13.2 billion yen (compared to 6.82 billion yen in the previous period), increasing the growth rate from 1.1% to 93.5%.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit is expected to increase 2.3 times, from the previous forecast of 4.85 billion yen to 11.1 billion yen (compared to 5.02 billion yen in the same period of the previous year), turning to a 2.2 times increase in the consolidated ordinary profit outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 Prev 68,261 4,951 4,850 3,745 65.2 32 Nov 7, 2024 J-GAAP
Oct - Mar, 2024 New 74,861 10,951 11,150 7,745 134.8 32 Apr 23, 2025 J-GAAP
Revision Rate +9.7% +121.2% +129.9% +106.8% +106.8%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 123,400 6,500 6,900 5,000 87.0 52 May 10, 2024 J-GAAP
Mar, 2025 New 130,000 12,500 13,200 9,000 156.7 52 Apr 23, 2025 J-GAAP
Revision Rate +5.3% +92.3% +91.3% +80.0% +80.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 64,595 4,899 5,244 3,585 62.5 32 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 74,861 10,951 11,150 7,745 134.8 32 Apr 23, 2025 J-GAAP
YoY +15.9% +123.5% +112.6% +116.0% +115.8%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 113,270 5,123 5,827 4,723 82.4 52 May 11, 2023 J-GAAP
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 Guidance 130,000 12,500 13,200 9,000 156.7 52 Apr 23, 2025 J-GAAP
YoY +8.8% +100.5% +93.5% +64.4% +64.2%

Related Articles